Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus
about
High-Risk Cardiovascular Patients: Clinical Features, Comorbidities, and Interconnecting MechanismsArterial distensibility in chronic inflammatory rheumatic disordersPredictors of the first cardiovascular event in patients with systemic lupus erythematosus - a prospective cohort study.Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.Systemic inflammation and early atheroma formation: are they related?The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus.Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patientsCould antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus?Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis.Cardiac manifestations of rheumatological conditions: a narrative reviewSemiquantified noncalcified coronary plaque in systemic lupus erythematosus.Establishing the diagnosis of Libman-Sacks endocarditis in systemic lupus erythematosusD-dimer level and the risk for thrombosis in systemic lupus erythematosus.The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus.Baseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients.European Forum on Antiphospholipid Antibodies: research in progress.Association of antiphospholipid antibodies with valvulopathy in systemic lupus erythematosus: a systematic review.Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.Libman-Sacks endocarditis as the first manifestation of systemic lupus erythematosus in an adolescent, with a review of the literature.Valvular heart disease in antiphospholipid syndrome.Pulmonary hypertension in antiphospholipid syndrome.Mitral Valve Perforation in Libman-Sacks Endocarditis: A Heart-Wrenching Case of LupusAnti-Ro/SSA antibodies are associated with severe mitral valve regurgitation in patients with systemic lupus erythematosus.Case 1: Acute chorea.Correlation of echocardiographic findings of pulmonary hypertension with six-minute walk test and plasma pro b-type natriuretic peptide level in systemic lupus erythematous.Is it antiphospholipid syndrome?Chinese SLE Treatment and Research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus.Features associated with cardiac abnormalities in systemic lupus erythematosus.Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.Influence of systemic lupus erythematosus on procedure selection and outcomes of patients undergoing isolated mitral valve surgery.Diabetes Mellitus and Ischemic Heart Disease: The Role of Ion Channels.Pulmonary arterial hypertension in SLE: what do we know?Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions.Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies.Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study.
P2860
Q26774658-1D83E0C3-D5F3-4708-BC55-2F54DB0BE6DAQ30481548-234B7712-8FA4-4FFB-A1C1-796856E3BAF3Q33387473-D67A369A-C386-4E03-929A-0868E741A62FQ34005307-27278C33-BBE3-475C-82EA-FEED793C2086Q35154761-0A191692-8E35-45AC-89C4-338DBBFBCC88Q35169351-971DCECC-DFD6-40F8-B639-445957517AD3Q35209597-04A31466-42FE-4EA7-8B44-69FAFA8B2B3CQ35953555-2ED69AA2-9EAA-4F25-BC79-D196676DC3F8Q36346769-E88B9691-0C36-41B8-9537-0AA406A66175Q36355415-C6EDB15F-9CEC-48D4-ADD6-27295523E558Q36709328-3D517E76-FFD3-4699-862D-7CA8013424FCQ36840557-FAB8F540-E1AD-4306-962A-BED9D6638C21Q36947358-A4FB267E-CB56-4456-A7D0-26A2E8D25015Q37206876-154A00AD-A653-44E9-81F3-EEB1841B4AE1Q37206944-39EE1816-B381-442E-975C-FD41379CDE6FQ37578126-E3AEC239-4E96-4C8C-B862-1D769AE737F8Q37826101-A761A74F-5347-4704-88C3-D92C9452E41BQ37853050-8B07EC28-58AE-4AF4-A523-EE57FEED8E7FQ38027000-7522531E-CBFB-4733-AF46-EB612926D074Q38086166-49F192DE-188E-45E2-A836-6619D1127127Q38325716-14E816CB-0327-4202-A51D-784FECBC592BQ38774615-3663D286-4FB4-4801-A6C7-EC5EA6804FE5Q38899667-F9735345-F021-422F-B4D5-851A1D7D305DQ39421351-0419B43A-67D2-4115-AF7B-4CD81D22CA0DQ42364232-447D1A40-A995-4ABB-99ED-44C442D6E05CQ42591326-666435C7-0BAB-4408-88E5-48264F519357Q44490545-63D564FD-B912-49AF-9690-5AFF37E8AC2CQ46118003-B343879A-9E5F-49A3-9BBB-C9063B9E7A8EQ50052184-DBDCB034-06B5-4324-A618-048F11189293Q51361404-CCA6DDE1-32F2-46D4-B8A3-264D6B382471Q52357267-E4CCB9D9-1197-428F-A008-1871858E62BAQ53102154-C567C224-0952-48D8-B9F0-0ACDF2D356FEQ53159273-3BB65F56-C5FA-4BCA-9578-3450BCEB84CAQ54052789-2BE084F6-92B7-4E0A-8AF9-1E49FAE368ADQ54963891-653C2ADB-FC34-4A63-93A6-68B2B04AD5A3
P2860
Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в грудні 2006
@uk
name
Relationship of antiphospholip ...... f systemic lupus erythematosus
@en
Relationship of antiphospholip ...... f systemic lupus erythematosus
@nl
type
label
Relationship of antiphospholip ...... f systemic lupus erythematosus
@en
Relationship of antiphospholip ...... f systemic lupus erythematosus
@nl
prefLabel
Relationship of antiphospholip ...... f systemic lupus erythematosus
@en
Relationship of antiphospholip ...... f systemic lupus erythematosus
@nl
P2093
P2860
P356
P1476
Relationship of antiphospholip ...... f systemic lupus erythematosus
@en
P2093
Adrienne Davis
Afshin Farzaneh-Far
Daniel M Levine
Jane E Salmon
Lisa Sammaritano
Mary J Roman
Mary K Crow
Stephen A Paget
P2860
P304
P356
10.1002/ART.22265
P407
P577
2006-12-01T00:00:00Z